Adarza, based in Maryland Heights, makes diagnostic systems for researchers and drug companies. It plans to launch its testing platform commercially in June.
Biotech company Adarza BioSystems announced today that it has raised $25 million in a Series D round co-led by 3×5 Partners, based in Portland, Ore., and St. Louis-based Lightchain Capital, LLC, the family office of Scottrade founder Rodger Riney.
Adarza plans to use the funds to support full commercialization of ZIVA, its automated biological testing platform for academic and clinical research. Scheduled for commercial launch in June, the ZIVA platform will allow researchers to quickly identify inflammation, cardiovascular, and oncology protein biomarkers for disease profiling and drug development.
Adarza Biosystems, Inc. announced today that it will reveal its new protein multiplex instrument ZIVA at Immunology 2019, the annual meeting of the American Association of Immunologists (AAI) from May 9 – 13. Using a simple, time-saving workflow, the new automated system can simultaneously measure, analyze and report on up to 200 biomarkers.